GlaxoSmithKline (GSK)’s recently announced $4.2 billion partnership to co-develop and co-commercialize Merck KGaA, Darmstadt’s cancer immunotherapy candidate M7824 was a reminder of just how much biopharma giants are willing to invest in a therapeutic area that has generated sometimes-dazzling results. How high is up for immuno-oncology? Numerous firms have ventured their best projections for the […]
Original Article: Top 10 Immuno-Oncology Startups